THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ:AMGN) today announced Amgen™ Oncology Assistance (AOA), a comprehensive, multi-faceted financial assistance program that will include a “cap” on out-of-pocket co-payments for cancer patients receiving Vectibix™ (panitumumab). Through AOA, patients who are uninsured, underinsured, or unable to afford their insurance co-payments will receive help obtaining financial support for Amgen’s cancer medicines.
